ESR1 and breast carcinoma: In conclusion, the findings presented here help to explain why the cancerous cells of a subset of patients with ERα+ breast cancer tend to spread to distant locations, and nPAK4 may be a novel biomarker molecule with potential value in clinical practice for predicting metastasis to the bone.